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Abstract
In HIV disease, the mechanisms of drug-resistance are only poorly understood. Incomplete suppression of HIV by antiretroviral
agents is suspected to be a main reason. The objective of this in silico study is to elucidate the pharmacokinetic origins of incomplete
viral suppression, exemplified for zidovudine (AZT) as a representative of the key class of nucleoside reverse transcriptase inhibitors
(NRTIs). AZT, like other NRTIs, exerts its main action through its intracellular triphoshate (AZT-TP) by competition with
natural thymidine triphosphate. We developed a physiologically based pharmacokinetic (PBPK) model describing the intracellular
pharmacokinetics of AZT anabolites and subsequently established the pharmacokinetic-pharmacodynamic relationship. The PBPK
model has been validated against clinical data of different dosing schemes. We reduced the PBPK model to derive a simple three-
compartment model for AZT and AZT-TP that can readily be used in population analysis of clinical trials. A novel machanistic,
and for NRTIs generic effect model has been developed that incorporates the primary effect of AZT-TP and potential secondary
effect of zidovudine monophosphate. The proposed models were used to analyze the efficacy and potential toxicity of different dosing
schemes for AZT. Based on the mechanism of action of NRTIs, we found that drug heterogeneities due to temporal fluctuations
can create a major window of unsuppressed viral replication. For AZT, this window was most pronounced for a 600mg/once daily
dosing scheme, in which insufficient viral suppression was observed for almost half the dosing period.
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1. Introduction
Highly active antiretroviral therapy (HAART), in which
three or more drugs are given in combination, has substan-
tially improved the clinical management of human immun-
odeficiency virus (HIV) infection (Richman, 2001). How-
ever, the emergence of drug-resistant variants eventually
leads to therapy failure in most patients (Struble et al.,
2005; Tozzi et al., 2006). Up to now, the mechanisms of drug
resistance are poorly understood. In (Kepler and Perel-
son, 1998), it is suggested that drug heterogeneity might
create viral sanctuaries in which replication remains sta-
ble, allowing for resistance to develop and manifest (Kepler
and Perelson, 1998; Pierson et al., 2000). Furthermore, as
drugs are administered at discrete times so that the drug
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concentration fluctuates temporally, they suspected that
there may be a similar window of insufficient viral suppres-
sion due to temporal inhomogeneities. This hypothesis, al-
though supported bymany experimental findings (reviewed
in (Schrager and D’Souza, 1998; Blankson et al., 2002)),
has not been thoroughly analyzed in silico. In fact, only few
mathematical models of HIV dynamics relate the degree of
viral suppression to in vivo pharmacokinetics and pharma-
codynamic parameters (Huang et al., 2003; Rosario et al.,
2005; Dixit et al., 2004; Dixit and Perelson, 2004).
Most anti-HIV drugs act on intracellular targets (Owen
and Khoo, 2004), and a high percentage of these drugs are
substrates of some efflux transporters (Eilers et al., 2008;
Janneh et al., 2005, 2007; Weiss et al., 2007; Hayashi et al.,
2006). For the class of nucleoside reverse transcriptase in-
hibitors (NRTI), the current backbone of HAART, their
pharmacological penetration into the target tissue/cells de-
pends not only on the presence of transporters, but also on
a cascade of intracellular activation (Painter et al., 2004).
The abundance of the involved enzymes, and the affinity
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of the drug to the enzymes are important determinants of
drug disposition.
For this class of pharmaceutics, the active intra-cellular
moieties rather than the plasma markers are the impor-
tant determinants relating to drug efficacy (Fletcher et al.,
2000). Determining intracellular drug levels is usually
costly, time-consuming and non-standard (Becher et al.,
2002b,a; Compain et al., 2007). Understanding the intra-
cellular pharmacokinetics of NRTIs, where the triphos-
phate moiety exerts the pharmacological action (Peter and
Gambertoglio, 1998; Piliero, 2004; Painter et al., 2004),
will therefore enhance our understanding of the evolution-
ary dynamics of HIV under NRTI treatment.
In this article, we focus on the thymidine analogue zi-
dovudine (AZT) (Wilde and Langtry, 1993), as a represen-
tative of the class of NRTIs. In the case of AZT, the active
triphosphate (AZT-TP) competes with the natural sub-
strate deoxythymidine triphosphate (dTTP) for the reverse
transcriptase of HIV. AZT-TP, once incorporated into the
viral DNA chain, leads to chain termination and thereby in-
hibits virus proliferation (Langtry and Campoli-Richards,
1989).
Many studies focus on the pharmacokinetics of the pro-
drug, assuming a linear relationship between AZT and
its active anabolite (e.g. (Panhard et al., 2007; Capparelli
et al., 2003)). However, the relation between AZT and
AZT-TP was shown to be non-linear (Wattanagoon et al.,
2000; Stretcher et al., 1991; Anderson et al., 2003; Barry
et al., 1996; Rodman et al., 1996; Aweeka et al., 2007).
Since NRTIs exert their pharmacological activity
through competition with naturally occurring deoxynu-
cleotide triphosphates, it has been shown for the class
of NRTIs (Arts et al., 1996), and specifically for AZT
(Fridland et al., 1990), that the nucleoside analogue
triphosphate-to-deoxynucleotide triphosphate ratio is a
major determinant for successful chain termination by NR-
TIs. In the case of AZT it has been shown that the main
anabolite, zidovudine monophosphate (AZT-MP), causes
depletion of dTTP levels (Furman et al., 1986; Fridland
et al., 1990), which might be synergistic to the effect of
AZT-TP on the reverse transcriptase of HIV.
So far there is no pharmacokinetic model which explic-
itly includes the phosphorylation cascade of AZT to AZT-
TP. The objective of the present study is to build a detailed
PBPK model for zidovudine and its anabolites, based on
in vitro and in vivo data. This allows us to study the ori-
gins of drug heterogeneity and the extent, to which tem-
poral fluctuations can create windows of insufficient viral
suppression—with the aim to help interpret outcomes of
clinical trials (Shepp et al., 1997; Ruane et al., 2004). The
proposed models, in particular the effect model, are appli-
cable to investigate other NRTIs.
2. Material and methods
2.1. Clinical trials on AZT and anabolites
pharmacokinetics.
Intracellular levels of AZT and its anabolites are very
difficult to obtain and therefore only few clinical studies
focus on the intracellular in vivo pharmacokinetics of AZT
anabolites.
Since peripheral blood mononuclear cells (PBMCs) con-
tain CD4+-cells, the main target of HIV, they are currently
used as a marker for target cell penetration of activated
AZT moieties. The studies used for model validation are
assessing AZT anabolite levels in PBMCs after various oral
doses of zidovudine (Barry et al. (1996): 100mg; Aweeka
et al. (2007); Barry et al. (1996): 300mg; Flynn et al. (2007):
600mg) in HIV infected patients. The utilization of differ-
ent doses allows us to identify concentration-dependent in
vivo kinetics.
Tissue-to-plasma (or tissue-to-blood) partitioning coef-
ficients are among the most important compound-specific
input parameters in physiologically based pharmacokinetic
modelling. For obvious reasons, these parameters are ob-
tained from laboratory species, like rat, mouse, etc and sub-
sequently extrapolated to assess human pharmacokinetics.
We will utilize this strategy by considering the information
about tissue partitioning from a study in mice (Chow et al.,
1997). We chose this particular study, since it distinguishes
between the different anabolites of AZT.
Table 1
Patient characteristics for the literature data that have been used
to evaluate the pharmacokinetic model. The steady state indicates
whether the patients in the respective study where in pharmacoki-
netic steady state prior to the start of the study (”Y” = Yes, ”N”
= No). † healthy volunteers with a reference CD4+-count (Bisset
et al., 2004). ‡ set to reference weight
ref. mean weight mean CD4+ count steady state
Barry et al. (1996) 72.1 [kg] 221 [106 cells/L] Y
Serra et al. (2008) 60[kg] 800† [106 cells/L] N
Aweeka et al. (2007) 90.3 [kg] 503 [106 cells/L] Y
Flynn et al. (2007) 70‡ [kg] 550 [106 cells/L] Y
2.2. Detailed physiologically based pharmacokinetic model
of zidovudine and its anabolites
The physiologically based pharmacokinetic (PBPK)
model structure of zidovudine and its mono-, di- and tri-
phosphate anabolites is illustrated in Fig. 1A. The PBPK
model consists of three anatomical compartments: blood,
PBMCs, and ’rest of body’. PBMCs are included as an
anatomical compartment due to their importance in HIV
dynamics. They consist of different cell types, of which the
largest fraction are T-cells (in healthy volunteers (Bisset
et al., 2004)).
2
AZT and AZT-MP are able to permeate cellular mem-
branes, while the di- and triphosphate moiety are confined
to the cellular spaces (Chow et al., 1997; Arne´r et al., 1992).
It has been observed that the cellular amounts of zidovu-
dine diphosphate (AZT-DP) and AZT-TP are significantly
smaller than the corresponding AZT and AZT-MP levels
(approximately 1:100) (Wattanagoon et al., 2000; Barry
et al., 1996; Rodman et al., 1996; Aweeka et al., 2007;
Toyoshima et al., 1991; Furman et al., 1986; Arne´r et al.,
1992; Flynn et al., 2007). The levels of di- and triphosphates
in the rest of the body insignificantly influence the kinet-
ics of AZT and AZT-MP (Chow et al., 1997). Therefore,
will model the di- and tri-phosphate species only in the ef-
fect compartment, i.e., the PBMCs. This assumption will
subsequently allow us to derive a very simple, mechanism-
based effect model.
The resulting system of differential equations including
a detailed description of the kinetics is given in the sup-
plementary material; corresponding parameter values are
given in Tables 2 and 3.
Table 2
Estimated pharmacokinetic parameters.
estimated pharmacokinetic parameters
param. value param. value param. value
KeMP:AZT 6.14 v−3 [mL/h] 0.07 Vmax[pmol/h] 135
2.2.1. Physiology
The total body weights have been reported in the clinical
trials (see Sec. 2.1). We assume a density of 1 [kg/L] to
convert body weight to volume, and set Vbody equal to the
mean body volume of the respective trial. The total blood
volume Vb is set to be 5.4 [L] (Brown et al., 1997). The
volume of the ’rest of body’ compartment Vr is given by
Vr = Vbody − Vb − Ve, where Ve denotes the volume of the
PBMCs. This has been estimated in the following way: The
reference volume of a PBMC cells Ve has been identified
with the volume of a T-cell, V T-cell = 140[fL] (Begenisich
et al., 2004). The total number of PBMCs is the sum of
the CD4+ and CD4− cells. The former are available for the
different studies (Barry et al., 1996; Aweeka et al., 2007;
Flynn et al., 2007; Marier et al., 2007), while the latter has
been set to 800 [106 cells/L] (based on an average total
PBMC count of 1600 in healthy subjects, with a CD4−
fraction of ∼ 50%) (Bisset et al., 2004).
The literature parameters are displayed in Table 3. Three
parameters (the maximal phosphorylation velocity of AZT-
MP Vmax = 135 [pmol/h], the velocity of AZT-DP de-
phosphorylation v−3 = 0.07[mL/h] and the ratio of AZT-
MP-to-AZT in PBMCs KeMP:AZT = 6.14) were estimated
from the in vivo data.
2.2.2. Pharmacokinetic parameter estimation
The parameter estimation was performed by the op-
timization routine lsqcurvefit in MATLABr, using a
weighted least-squares criteria to estimate the goodness of
fit, according to:
err =
∑
i
|C(ti; p)− Cexp(ti)|2
C(ti; p)
, (1)
where p denotes the vector of parameters that have to be
estimated. The values ti and Cexp(ti) represent the experi-
mental time points and the corresponding concentrations,
respectively. The concentrations C(ti; p) are determined as
the numerical solution of the model equations with param-
eters p, evaluated at time points ti. The relevant study
and patient characteristics used for validation are given in
Sec. 2.1.
2.3. Reduced pharmacokinetic model suitable for
population analysis
PBPKmodels have generally too many parameters to al-
low for a reliable estimation of individual parameters of the
entire model in the context of population analysis of clinical
trials. In order to facilitate the use in this context, we will
reduce the detailed PBPKmodel to a simpler compartment
model. Analysis of the PBPK model yields the following
insights: First, the concentrations of AZT and AZT-MP in
the three anatomical compartments blood, ’rest of body’,
and PBMC are in quasi steady state. They can be related
to each other and to the plasma concentration of AZT by
some proportionality factor. Second, the concentrations of
AZT-DP and AZT-TP in the PBMCs are in quasi steady
state so that they can be related to each other by some pro-
portionality factor. Third, AZT/AZT-MP and AZT-DP/-
TP are not linked by some constant factor, which is due to
competitive and non-competitive inhibition of the thymidy-
late kinase by AZT-MP Lavie et al. (1997). Fourth, the de-
phosphorylation of AZT-DP has a negligible influence on
the total AZT-MP concentration.
Hence, we propose a three compartment model. It com-
prises a central AZT compartment (volume V1 and con-
centration C1), a peripheral AZT compartment (volume
V2 and concentration C2), and an AZT-TP effect compart-
ment (volume V 3 and concentration C3). The volume V3 is
related to the CD4 counts via V3 = V T-cell (CD4+count +
CD4−count) Vb. The inter-compartmental clearance be-
tween the central and peripheral compartment is denoted
by Q; and dosing refers to the application of the drug (e.g.,
p.o. or i.v.). Then, the system of ODEs is given by
V1
d
dt
C1 =Q · (C2 − C1)− CL1 · C1 + dosing (2)
V2
d
dt
C2 =Q · (C1 − C2) (3)
V3
d
dt
C3 =
Kmax ·M1
KMPm
(
1+ dTMP
KdTMPi
)
+M1
(
1+ M1
KMPi
) − v−3C3 (4)
M1 =Ke:bMP:AZT · C1. (5)
3
v1/2:   Thymidine kinase 1 (proliferating cells) 
 Thymidine kinase 2 (mitochondria, resting cells)
 v-1/-2:  Thymidine monophosphatase nucleotidase;   
PBMC 
diffusion/
transport
dose
clearance
AZT
AZT-MP
v-1
v1
AZT-DPAZT-TP
v-3v-4
v4
Hypothesis
-substrate inhibition
v3
AZT
AZT-MP
Blood
diffusion/
transport
AZT
AZT-MP
Rest of Body
v-2
v2
v3:  Thymidylate kinase
v-3: Adenosine diphosphatase 
residual
A
B
detailed PK-
model
Q
CL1
dosing
central
   AZT
peripheral
      AZT
 effect
(PBMC)
AZT-TP
reduced PK-
model
v4:  Nucleoside diphosphate kinase
 3-Phosphoglycerate kinase
v-4: Thymidine triphosphatase
 Adenosine diphosphatase
model reduction population pharmacokinetics
V2V1
Fig. 1. A. Physiologically based compartment model for the PK of zidovudine and its anabolites. The corresponding system of ordinary
differential equations is given in the supplementary material. B. Reduced PK model. The active intracellular AZT-TP is described as a
function of the plasma AZT levels.
Table 3
Physiological, pharmacokinetic and pharmacodynamic literature parameters. For a description of the parameters see supplementary material.
physiological
param. value ref. param. value ref.
V b [L] 5.4 (Brown et al., 1997) CD4− [106cells/L] 800 (Bisset et al., 2004)
V T−cell [fL/cell] 140 (Begenisich et al., 2004) - - -
pharmacokinetic
CL [L/min] 1.56 (Acosta et al., 1996) KMPm [µM] 6 (Lavie et al., 1997)
B: P 0.86 (Luzier and Morse, 1993) KrMP:AZT 0.071 (Chow et al., 1997)
F 0.64 (Wilde and Langtry, 1993) vfast[L/min] 1·105 -
fup 0.75 (Luzier and Morse, 1993) KDP:TP 1.1 (Flynn et al., 2007)
KMPi [µM] 30 (Lavie et al., 1997) dTMP [µM] 1.4 (Traut, 1994)
kA [min
−1] 0.022 based on tmax (see text) Kup:eAZT 1 (Zimmerman et al., 1987)
pharmacodynamic
KdTMPm ,K
dTMP
i [µM] 9 (Lavie et al., 1997) K
RT
m,TP[µM] 2.42 (Cases-Gonzlez and Menndez-Arias, 2005)
KRTm,dTTP[µM] 0.32 (Cases-Gonzlez and Menndez-Arias, 2005) dTTP(0)[µM] 4.1 (Traut, 1994)
Above, M1 denotes the AZT-MP concentration in the ef-
fect compartment, which is related to the concentration of
AZT in the central compartment by the ratio Ke:bMP:AZT =
KeMP:AZT · fup/(Kup:eAZT · B:P). The parameter Kmax de-
notes the apparent maximal conversion rate from AZT-
MP to AZT-TP (via AZT-DP), which is given by Kmax =
Vmax/(1 + KDP:TP); and KMPm denotes the corresponding
Michaelis-Menten constant. The parameter v−3 denotes the
apparent dephosphorylation rate constant of AZT-TP, and
dTMP denotes the deoxythymidine monophosphate con-
centration. Finally, KdTMPi and K
MP
i denote the corre-
sponding non-competitive and competitive inhibition rate
constants related to the conversion from the mono- to the
di-phosphate.
Eq. (4) has been directly derived from the phophoryla-
tion and de-phophorylation reaction velocities in the de-
tailed PBPK model (see supplementary material) under
the above stated assumptions. It explicitly accounts for the
competition with dTMP and the substrate inhibition by
AZT-MP. We remark that the AZT plasma concentration
acts only as an input into the AZT-TP effect compartment
kinetics; there is no influence of C3 on the kinetics of C1
4
and C2. This also implies that any model on AZT plasma
kinetics (e.g., (Panhard et al., 2007; Gitterman et al., 1990;
Mirochnick et al., 2007)) could be used to link it to the
AZT-TP kinetics in eq. (4).
The compartment model (2)-(5) contains the 4 indepen-
dent parameters: V1, V2, Q and CL1, in addition to dosing.
The remaining parameters are given in Table 3 and 2, while
CD4+ CD4- counts (entering V3) have to be measured ex-
perimentally for each patient.
2.4. Pharmacodynamics
The target of ziduvodine and its anabolites is the process
of reverse transcription. The effect is based on decreasing
the likelihood of successful viral reverse transcription, i.e,
DNA chain completion. AZT-TP competes with the nat-
ural substrate deoxythymidine triphosphate (dTTP) for
binding to the reverse transcriptase (RT) and subsequent
insertion into the DNA. AZT-TP insertion leads to DNA
chain termination, thus inhibition of the reverse transcrip-
tion process (Langtry and Campoli-Richards, 1989).
We aim at an effect model that accounts for the (i) com-
petition between AZT-TP and dTTP for binding to the
RT and subsequent insertion into the DNA chain, (ii) the
reaction time for insertion, (iii) the fact that successful
DNA chain completion requiresN consecutive insertions of
dTTP, and (iv) the fact that successful insertion of AZT-
TP leads to a termination of chain prolongation and sub-
sequent DNA chain degradation, such that the process of
reverse transcription has to start again. Our starting point
for modelling the effect of AZT-TP is to consider the likeli-
hood of a single dTTP insertion, depending on competition
with AZT-TP (see Fig. 2C).
If the discreteness of the reaction events and its sequence
are important, the stochastic model of chemical reaction
kinetics (Turner et al., 2004) is a much more appropriate
description than the deterministic reaction rate model. In
the stochastic setting, a bio-chemical reaction R is speci-
fied in terms of a so-called propensity functions aR that is
the probability that the reaction will take place in the next
infinitesimal time interval. The propensity depends on the
reaction constants and the abundance of the involved reac-
tants. It is related to the next reaction time τ by E(τ) =
1/aR, where E(τ) denotes the expected (mean) time to the
next reaction event. In the case of two competing reactions
R1 and R2 the expected time to the next reaction (either
R1 orR2) isE(τ) = 1/(aR1+aR2). After this time, reaction
R1 will take place with probability aR1/(aR1+aR2) and re-
action R2 will take place with probability aR2/(aR1+aR2).
In the sequel we will use the abbreviations TP for AZT-
TP and MP for AZT-MP. The propensity a+(AZT) of pro-
longation of the DNA chain by a single dTTP in the pres-
ence of TP is given by
a+(AZT) =
kcat · RT · dTTP
KRTm,dTTP
(
1 + TP
KRTm,TP
)
+ dTTP
, (6)
where kcat [1/s] is the rate of insertion, and RT denotes the
number of reverse transcriptases (Rao and Arkin, 2003).
The parametersKRTm,dTTP andK
RT
m,TP denote the Michaelis-
Menten constants for insertion of dTTP and TP, respec-
tively. Analogously, the propensity a0(AZT) of termination
of the DNA chain by insertion of a single TP in the pres-
ence of dTTP is given by
a0(dTTP) =
kcat · RT · TP
KRTm,TP
(
1 + dTTP
KRTm,dTTP
)
+TP
. (7)
Based on the above two propensities, we can compute the
probability q of dTTP insertion (under the condition that
either AZT-TP or dTTP is inserted) according to
q =
a+(AZT)
a0(dTTP) + a+(AZT)
=
1
1 + TPdTTP ·
KRTm,dTTP
KRTm,TP
. (8)
Here, we used the fact that kcat for dTTP and AZT-TP
incorporation are identical (Cases-Gonzlez and Menndez-
Arias, 2005), so that kcat and RT cancel out and q only
depends on dTTP, AZT-TP, and the parameters KRTm,dTTP
and KRTm,TP. After chain completion, the RT returns to the
initial state with probability one (see Fig. 2C).
Successful completion of the viral DNA requires the in-
corporation of N = 2042 or N = 3272 thymidine bases
for the DNA-DNA and RNA-DNA direction, respectively
(GenBank accession no.AF033819). The effect of zidovu-
dine and its anabolites is the deceleration of the reverse
transcription process, i.e., the fraction p of successful DNA
chain completion in comparison to the untreated situation.
Equivalently, the effect can be interpreted as the increase
1/p in the mean time needed to successfully complete re-
verse transcription in comparison to the no-drug situation.
Interpreting the effect model as a Markov chain allows us
to determine the expected time to completion of the reverse
transcription process in the presence of AZT EAZT[τDNA]
(see supplementary material) and the reduction p of DNA
chain completion as p = E0[τDNA]/EAZT[τDNA], or
p=
a+(AZT) + a0(dTTP)
a+(0)
·NqN · 1− q
1− qN . (9)
The smaller p, the smaller the viral replication and there-
fore the more effective the drug. After a slight rearrange-
ment of the above equation we obtain:
p=
a+(AZT)
a+(0)
·NqN−1 1− q
1− qN . (10)
The overall effect p can be further divided into a primary
effect associated with AZT-TP, and a secondary effect asso-
ciated with AZT-MP. The monophosphate has been shown
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Fig. 2. AZT exerts its effect through AZT-TP and AZT-MP. Panel A: AZT-MP binds to a regulatory site of thymidylate kinase, reducing
the catalytic efficacy of the enzyme. This can lead to depletion of dTTP levels, giving AZT-TP a competitive advantage over dTTP for the
incorporation into the growing HIV-DNA. Panel B: AZT-TP competes with dTTP for incorporation into the growing DNA chain of HIV.
If AZT-TP is incorporated, it leads to DNA chain termination. Incorporation of dTTP leads to DNA-chain prolongation. Panel C: Reverse
transcriptase needs to incorporate N = 2042 (DNA-DNA) or N = 3272 (RNA-DNA) thymidine bases for successful completion of the viral
DNA. The probability of successful thymidine incorporation is denoted by q. After chain termination, incomplete DNA is released and reverse
transcription starts from the beginning.
to inhibit the thymidylate kinase competitively as well as
non-competitively (Lavie et al., 1997). This enzyme is re-
sponsible for both the activation of AZT and deoxythymi-
dine. The inhibition by AZT-MP causes depletion of dTTP
levels (see Fig. 2A, and supplementary material).
3. Results
3.1. Detailed PBPK model predicts experimental data of
AZT and anabolites across different studies.
We have validated the PBPK model with experimental
data across different clinical studies, utilizing different dos-
ing schemes. The simulated and the clinical data show good
agreement (see Fig. 3 (left) and supplementary material).
In Fig. 3 (right) we show a sample profile for an oral dose of
600mg AZT. The model simulations show a linear relation
between plasma AZT and intra-cellular AZT-MP, a linear
relation between AZT-DP and -TP, and a delayed relation
between AZT-MP and AZT-DP. The inset illustrates the
non-linear, saturable relation between AZT and AZT-TP
due to substrate inhibition.
Part of the existing deviation between simulated and clin-
ical data might be due to the large inter-individual vari-
ations in PBMC levels. In particular, it has been shown
that (i) the variations in intracellular AZT-TP levels in
PBMCs aremainly attributed to inter-individual variations
of drug concentration in CD3− and CD3+/CD4− cells in
the PBMCs compartment (Anderson et al., 2007); and (ii)
AZT-TP levels are lower in CD4+ cells than in the other
cells contained in PBMCs. The relation, however, has not
been fully resolved yet (Anderson et al., 2007). These two
facts are likely to contribute to existing deviations.
3.2. In silico analysis of toxicity and pharmacodynamics
for different dosing schemes
We used the PBPK model to analyze concentration
time profiles of AZT-MP and AZT-TP for different dosing
schemes in a 72 [kg] HIV positive human with CD4+-count
of 65 (fraction CD4+ in the CD3+ gate: 0.14): (a) 100mg
six times a day (b) 100mg three times a day, (c) 300mg
two times a day; and (d) 600mg once daily. The predicted
6
10−3 10−2 10−1 100 101
10−3
10−2
10−1
100
101
simulated data
ex
pe
rim
en
ta
l d
at
a
 
 
Barry et al. (1996)
Dos Reis Serra et al. (2008)
Barry et al. (1996)
Aweeka et al. (2007)
Flynn et al. (2007)
0 2 4 6 8 10 12 140
20
40
time [h]
AZ
T &
 A
ZT
−M
P 
[µM
]
 
 
0
0.2
0.4
AZ
T−
DP
 &
 A
ZT
−
TP
[µM
]
AZT
AZT-MP
AZT-DP
AZT-TP
0 2 4 6 8 100
0.1
0.2
0.3
0.4
0.5
AZT [µM]
AZ
T−
TP
 [
µ
M
]
Fig. 3. Left panel: Simulated versus measured clinical data from Aweeka et al. (2007); Barry et al. (1996); Flynn et al. (2007); Serra et al.
(2008). Clinical data comprises AZT (plasma) and AZT-MP, AZT-DP and AZT-TP in the PBMCs following oral doses of 100, 300 and
600 [mg] zidovudine. Right panel: Sample profile for an oral dose of 600 [mg] zidovudine at steady state. The inset illustrates the saturable
relation of AZT to AZT-TP (cf. eq. (4)).
concentration time profiles together with the experimental
data from the different clinical studies are shown in the
supplementary material. A summary related to exposure
of AZT-MP and percentage residual RT activity is given
in Table 4. The 100mg six times daily scheme outperforms
the other dosing schemes with regard to intracellular AZT-
TP levels, while the 600mg once daily dosing scheme is
very inefficient compared to the other schemes. Regarding
the exposure to AZT-MP, which is often connected to toxi-
city (To¨rnevik et al., 1995; Lynx et al., 2006; Susan-Resiga
et al., 2007), the 100mg three times daily dosing scheme
provides the smallest exposure to AZT-MP, while the ex-
posure to AZT-MP is comparable for the other dosing
schemes.
The inset in Fig. 3 (right) shows that the concentration
of AZT-TP does not linearly increase with increasing AZT
concentration. The AZT:AZT-TP graph shows the typical
behavior of substrate inhibtion: increasing doses of AZT
result in increasing concentrations of AZT-MP, which, on
one hand, is converted into AZT-TP (via AZT-DP) and on
the other hand inhibits its own conversion. Higher doses of
AZT thus result in higher concentration of AZT-MP, but
not AZT-TP.
3.3. Reverse transcription under AZT treatment
The percent of successful viral DNA reverse transcrip-
tion under AZT treatment is shown in Figure 4 (left) for
the different dosing schemes. It has been predicted based
on eq. (9). The impact of low AZT-TP concentrations at
the end of each dosing interval is most pronounced in the
600mg once daily dosing scheme. For the latter, the ac-
tive drug concentration is insufficient for almost the entire
second half of the dosing interval, leading to ineffective in-
hibition of the reverse transcription process. This lack of
effect coincides with the time at which levels of AZT-TP
drop below approximately 0.05 [µM], and at which almost
no dTDP depletion remains (see supplementary material).
This implies that the chance of mutational viral escape is
rising at the time before the next dosing in case of less fre-
quent dosing. We evaluated the % of residual RT activity
(relative to the absence of AZT) in Table 4 for a 24h in-
terval after reaching steady state (day 3-4). It can be seen
that for the 600mg dosing scheme insufficient inhibition
(approx. 80 %) is reached in PBMCs.
Table 4
Exposure to AZT-MP and the efficacy of the treatment during 24h
after pharmacokinetic steady state (day 3-4). The efficacy is ex-
pressed in % of residual RT activity during the 24h interval.
dosing scheme AUC0−24 (AZT-MP) % res. RT activity
100mg every 4h 70.4 [h·µM] 3.6 · 10−8
100mg every 8h 35.4 [h·µM] 5.9 · 10−2
300mg every 12h 70.8[h·µM] 0.26
600mg every 24h 70.8 [h·µM] 18.9
3.4. The effect of AZT-TP is highly sensitive to changes
in the AZT-TP:dTTP ratio
The probability q of a successful thymidine incorpora-
tion enters the effect model to the (N -1)th power, where
N denotes the number of thymidine bases to be inserted
into the growing DNA chain. It is a function of the AZT-
TP:dTTP ratio, see Fig. 4 (right). It can be seen that the
effect of AZT-TP is highly sensitive to fluctuations in in-
tracellular AZT-TP levels. For the reference ratio of the
Km values reported in Cases-Gonzlez and Menndez-Arias
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Fig. 4. Left panel: Residual virus DNA production for different dosing schemes after the initiation of AZT therapy. The curves show the %
residual reverse transcription (based on eq. (10)) after a once daily dose of 600 [mg] (dashed magenta line), a twice daily oral dose of 300
[mg] (solid black line), an oral dose of 100 [mg] every 8 hours (dash-dotted blue line) and an oral dose of 100 [mg] every 4 hours (dotted red
line). Right panel: Influence of the dTTP:AZT-TP ratio on the suppression of reverse transcription for different KRTm,dTTP : K
RT
m,TP ratios.
The solid line corresponds to the literature KRTm,dTTP : K
RT
m,TP ratio, while the other values are chosen to illustrate the impact of resistance
mutation (rightmost lines) or hypersensitivity (leftmost lines) on % residual reverse transcription.
(2005)—represented by the bold line in Fig. 4 (right)—we
would expect the largest sensitivity for AZT-TP:dTTP
ratios in the order of 10−3 - 10−2. The pharmacokinetic
fluctuations in intracellular AZT-TP:dTTP ratios were in
the range: 0.08-0.16 (100mg/4h) 0.02-0.09 (100mg/8h),
0.016-0.2 (300mg/12h), 0.0014-0.25 (600mg/24h). Hence,
the largest impact of drug fluctuations is expected for the
300mg and the 600mg dosing scheme, in accordance with
Fig. 4 (left).
3.5. The impact of resistance mutations
HIV develops resistance against zidovudine by two dis-
tinct mechanisms: (i) lowering the affinity of AZT-TP to
RT, and (ii) enhancing the ATP-dependent excision of in-
corporated AZT-TP (Clavel and Hance, 2004; Boyer et al.,
2001; Ray et al., 2003). In terms of our mechanistic ef-
fect model, both processes can be accounted for by in-
creasing KRTm,TP. This is illustrated in Fig. 4 (right), where
the solid line corresponds to the reference ratio, while the
other curves demonstrate the impact of resistance mutation
(rightmost lines) or hypersensitivity (leftmost lines) on %
residual reverse transcription. As a net effect, changes in
KRTm,TP result in a shift of the most sensitive concentration
range in terms of the AZT-TP:dTTP ratio.
4. Discussion
In this article, we propose a PBPK model of zidovu-
dine and its anabolites. The PBPK model consists of a
blood compartment, a ’rest of body’ compartment and the
PBMCs as an effect compartment. Since zidovudine exerts
its main action through its triphosphate species, which is
produced from the parent compound through a cascade of
intra-cellular phosphorylation steps, these steps are explic-
itly taken into account. The majority of model parameters
were available from in vitro or in vivo experiments (see
Table 3); the remaining three parameters were estimated
from the in vivo data (see Table 2). The model was evalu-
ated against experimental in vivo data of different dosing
schemes (Barry et al. (1996): 100mg; Aweeka et al. (2007);
Barry et al. (1996): 300mg; Flynn et al. (2007): 600mg)
in HIV infected patients. While most studies only mea-
sure plasma levels of the pro-drug zidovudine, intra-cellular
PBMC levels of the active zidovudine anabolites are rarely
available. One aim of the current study is to use the avail-
able data in order to establish a link between the prodrug
and its active species.
The model predictions were generally in good agreement
with the experimental data (see Fig. 3 left). Despite their
large variability, data (see supplementary material) and in
silico predictions (see Fig. 3 right) clearly show (i) a lin-
ear relation between plasma AZT and intra-cellular AZT-
MP concentration; and (ii) a non-linear, time-delayed re-
lation between intra-cellular AZT-MP and intra-cellular
AZT-DP/TP levels. AZT and AZT-MP exhibit a shorter
halflife and peak time than the higher anabolites (AZT-DP
and AZT-TP) within the cells. All of these pharmacoki-
netic characteristics are very well reproduced by the model
predictions.
The focus of the current study is to establish a general
PK-PD relation rather than to optimize the fit to individual
experimental data. Pharmacokinetic variability can be at-
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tributed to various sources: e.g., in PBMCs, it has been re-
ported that the large variability in anabolite levels is mainly
contributed to variability of AZT-TP levels in CD4− cells
(within the PBMC compartment), which are not targeted
by HIV (Anderson et al., 2007). Since CD4− counts are
not available from the studies we did not attempt to in-
clude this factor into our model. We have parameterized
the PBPK model on the basis of experimental in vivo data
without further attempts to optimize these parameters.
In our PBPKmodelling context, we were able to upgrade
data on saturable AZT-MP phosphorylation from in vitro
experiments (Lavie et al., 1997) to the in vivo situation.
The pharmacokinetics of zidovudine and its anabolites
are attributed to the intra-cellular phosphorylation/de-
phosphorylation cascade. The enzyme kinetics of thymidy-
late kinase and AZT-MP are able to explain the de-
layed and saturable intracellular AZT-TP concentra-
tions. The longer halflife of the intracellular AZT-TP
(in comparison to plasma AZT) has its origin in a slow
de-phosphorylation of AZT-DP. No saturable steps were
found in the phosphorylation/de-phosphorylation step be-
tween AZT and AZT-MP, as well as between AZT-DP
and AZT-TP (see supplementary material). The in silico
predictions show the same non-linear relation between the
parent compound and the active species as the experimen-
tal data (Fig. 3 right, and supplementary material). Due
to the saturable kinetics, the model predicts that there
exists a maximal concentration of AZT-TP, beyond which
it would not be possible to further increase the levels of
intracellular AZT-TP with increasing doses of zidovudine.
In general, PBPKmodels do not aim at and are typically
not suitable for estimation of individual parameters in clin-
ical trials. This is the domain of population pharmacoki-
netics. In order to facilitate the transfer of our results into
population analysis of clinical data, we derived a reduced
compartment model. The saturable phosphorylation and
slow de-phosphorylation events in the intracellular phar-
macokinetics of AZT require to distinguish between plasma
levels & AZT anabolites with less than two phosphate
groups (AZT, AZT-MP) and the higher anabolites (AZT-
DP, AZT-TP). Consequently, we propose a three compart-
ment PKmodel of zidovudine in a central & peripheral com-
partment and the active species zidovudine triphosphate in
the PBMC effect compartment, see eqs. (2)-(4). The active
AZT-TP concentration is linked to the prodrug concentra-
tion in the central compartment via eq. (4). This relation
has been derived from the detailed PBPK model based on
the assumptions that AZT and AZT-MP as well as AZT-
DP and AZT-TP are linearly correlated, and that the influ-
ence of dephosphorylation of AZT-DP on AZT-MP levels
can be neglected due to a 100:1 ratio of AZT-DP:AZT-MP
levels. Although we proposed a two compartment model
for AZT, any compartment model of AZT could be used
to link central AZT levels to AZT-TP levels in the effect
compartment using the derived relation (4).
We have provided a quantitative assessment of the effect
of pharmacokinetic profiles of AZT-MP and AZT-TP on
suppression of reverse transcription. We used the proposed
PBPK- and effect model to analyze four different dosing
schemes in silico: 100 mg every 4 hours, 100 mg every 8
hours, 300 mg every 12 hours and 600 mg every 24 hours.
From our simulations, we conclude that the 100mg (every
8 hours) dosing scheme has the best properties regarding
(maximal) efficacy and (minimal) exposure to AZT-MP
(see Table 4), when taking the kinetics in PBMCs as a
reference for other target cells. In the case of the 600mg
once daily dosing scheme, incomplete suppression can be
seen in the time before the next dosing (Fig. 4, left). This
apparent lack of efficacy could explain the observed weaker
viral suppression for this dosing scheme in comparison
with the 300mg twice daily scheme (Ruane et al., 2004). It
is suspected to leave enough opportunities for viral escape
in PBMCs. The other dosing schemes provide very good
suppression of reverse transcription in PBMCs.When com-
paring the 300mg twice daily with the 100mg every 4 hours
dosing scheme, similar exposure to AZT-MP is found and
potent suppression of viral RT in both cases is observed
(Table 4). The results are in agreement with clinical trials
(Shepp et al., 1997), in which similar antiviral effects for
both dosing schemes were observed. Also, the associated
toxicity of both dosing strategies was comparable (Shepp
et al., 1997).
AZT-TP levels in CD4+ cells are sufficiently lower than
AZT-TP levels in other cells of the PBMC compartment
(Anderson et al., 2003, 2007). The exact relation has not
fully been resolved yet, however in (Anderson et al., 2007),
concentrations of AZT-TP in CD4+ cells were related to
the concentrations of AZT-TP in CD4+ depleted PBMC.
For the analyzed extent of CD4+ depletion (14 % CD4+
cells in the CD3+ gate) Anderson et al. (2007) found that
the levels in purified CD4+ cells are approximately 25% of
those in PBMCs. We might utilize this conversion factor
to predict the levels of AZT-TP in CD4+ cells based on
AZT-TP concentration in PBMCs. An analysis of the effi-
cacy based on this assumption is presented in Table 5.
Table 5
Efficacy expressed in % of residual RT activity during the whole
interval if the AZT-TP concentrations in CD4+ cells are 25% of
those in PBMCs, as suggested by Anderson et al. (2007).
dosing scheme [mg] 100 (/4h) 100 (/8h) 300 (/12h) 600 (/24h)
% res. RT activity 0.3 10 12 42
We infer that all dosing schemes, except for the 100mg
(every 4h) would insufficiently suppress viral replication in
CD4+ cells. However, this assumption remains speculative
until further data is available.
We propose a novel effect model to predict the impact
of zidovudine and its anabolites on the reverse transcrip-
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tion process. Our pharmacodynamic model considers the
competitive mode of RT binding and the resultant chain
termination mechanistically rather than empirically, utiliz-
ing experimental data from single nucleotide extension as-
says (Cases-Gonzlez and Menndez-Arias, 2005). The effect
is described by the deceleration of successful viral DNA
chain completion in the presence of zidovudine compared
to the situation without drug treatment. The two poten-
tial mechanisms, by which zidovudine acts, can be analyzed
separately. The primary effect is attributed to the insertion
of AZT-TP into the growing DNA chain. Once inserted,
the reverse transcription process is stopped, resulting in a
degradation of the uncompleted DNA chain. As a net re-
sult this process increases the time to successful comple-
tion of the DNA chain. It has been shown in (Arts et al.,
1996; Gao et al., 1999) that the AZT-TP:dTTP ratio is a
major determinant of antiviral efficacy. Based on our pro-
posed effect model, we can give a mechanistic justification
of this determinant. The parameter with most influence on
the overall effect is the probability of successful dTTP in-
corporation q. The relation between q, AZT-TP, dTTP and
the Km values is described by the very simple relation (8).
It states that the larger the quotient AZT-TP:dTTP, the
smaller q, as observed experimentally (Arts et al., 1996;
Gao et al., 1999). The second factor involved in eq. (8) is the
ratio KRTm,dTTP : K
RT
m,TP. Mechanistically, AZT-TP power-
fully inhibits reverse transcription due to the potentiation
of a low probability of incorporation by a large number of
opportunities for incorporation (Lavie et al., 1997). There-
fore, very small changes in the extent of incorporation q
can have a dramatic effect on the degree of inhibition. In
the light of our effect model (cf. eq.(10)), the probabil-
ity of successful thymidine incorporation enters the effect
model to the (N -1)th power, where N denotes the number
of thymidine bases that have to be inserted. Therefore, the
effect through AZT-TP is very sensitive to (a) variations
in the AZT-TP:dTTP ratio caused by depletion of dTTP
pools, or (b) temporal fluctuations in the AZT-TP concen-
trations caused by the pharmacokinetics after oral dosing
and (c) small modifications in the affinity of AZT-TP to
RT, e.g. as a result of mutations in the RT. Because the
effect of AZT-TP (and other NRTIs) is highly sensitive to
fluctuations in the AZT-TP:dTTP ratio, we speculate that
the heterogeneities in the AZT-TP (and most likely other
NRTI) levels can create a major window of unsuppressed
viral replication.
Resistance against AZT-TP was attributed to two dis-
tinct mechanisms (Clavel and Hance, 2004; Boyer et al.,
2001; Ray et al., 2003): (i) excision of AZT-TP from the
DNA chain, and (ii) decrease in affinity of RT to AZT-TP.
Both processes can be incorporated into our effect model
by increasing Km. The predicted impact of resistance on
the overall effect is shown in Fig. 4 (right) for multiple Km
ratios as a function of the AZT-TP:dTTP ratio.
The secondary effect of zidovudine is due to a potential
depletion of the natural nucleotide dTTP by AZT-MP. In
the absence of AZT-TP, this depletion has a minor influ-
ence on the deceleration of RT activity, while in the pres-
ence of AZT-TP, the dTTP:AZT-TP ratio is also modified,
which enters the parameter q in eq.(8) and thus has a large
influence.
Our proposed effect model is not restricted to zidovudine
but applicable to the broad class of NRTIs. The action of
non-nocleoside reverse transcriptase inhibitors (NNRTIs)
can also easily be incorporated into the effect model.
Most of the current models of HIV dynamics, e.g. (Perel-
son, 1999) and evolution, e.g. (Beerenwinkel et al., 2006)
are based on the assumption of constant drug concentra-
tions. Our results highlight the importance of drug phar-
macokinetics, in the case of zidovudine on the delay of vi-
ral DNA chain completion. For many drugs, the impact of
temporal fluctuations, attributed to the dosing schedule,
on the emergence of drug resistant strains has not been in-
vestigated.
The majority of HIV-target cells does not reside within
the blood compartment, but distributes widely in all
tissues, organs and anatomical compartments (Koenig
et al., 1986; Rappersberger et al., 1988; Stingl et al., 1990;
Tschachler et al., 1987; McElrath et al., 1989; Meltzer
et al., 1990), possibly serving as viral reservoirs (Stebbing
et al., 2004). For AZT, and possibly other NRTIs, inef-
ficient activation by intracellular enzymes constitutes a
major bottleneck for their use (Gail Skowron and Ogden,
2006) and might lead to sub-inhibitory concentrations.
The potential impact of spatial drug heterogeneity on
the emergence of drug resistance has been demonstrated
in silico in (Kepler and Perelson, 1998). In this study we
have demonstrated that temporal fluctuations may have a
similar impact on the emergence of drug resistance.
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